<DOC>
	<DOCNO>NCT01096381</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood urine laboratory patient cancer receive bevacizumab may help doctor learn change occur DNA identify biomarkers relate high blood pressure . PURPOSE : This phase I trial study potential biomarkers bevacizumab-induced high blood pressure patient malignant solid tumor , include breast cancer , colorectal cancer , non-small cell lung cancer , head neck cancer , ovarian cancer , fallopian tube cancer , primary peritoneal carcinoma .</brief_summary>
	<brief_title>Potential Biomarkers Bevacizumab-Induced High Blood Pressure Patients With Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : Primary - To measure endothelial function time , include non-invasive assessment digital-pulse amplitude via Endo-pat test , serum tPA , PAI-1 , VEGF , urine TXa2 , PGI-M , patient solid malignancy treat chemotherapy without bevacizumab . - To compare endothelial function change patient develop hypertension ( HTN ) versus patient develop HTN . Secondary - To compare circulate soluble cytokine , proangiogenic factor , glucose tolerance , cardiac biomarkers time patient . - To compare endothelial progenitor cell level pre- post-bevacizumab patient . - To assess whether physical fitness level baseline 3 month treatment initiation ( assess subjectively questionnaire ) correlate relative risk develop NCI grade ≥ I cardiotoxicity . OUTLINE : Patients undergo 24-hour blood pressure monitoring baseline , second bevacizumab therapy , periodically study . Patients also undergo digital-pulse amplitude measurement periodically study . Blood sample collect baseline periodically study circulate soluble cytokine , proangiogenic factor , glucose tolerance , cardiac biomarkers , endothelial progenitor cell level study . Patients also undergo 24-hour urine sample collection baseline periodically study protein , creatinine , metabolites prostacyclin thromboxane . Patients complete physical activity questionnaires baseline 3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients stage IV unresectable recurrent cancer ( except renal cell carcinoma glioblastoma multiforme ) get bevacizumab standard care , well patient initiate bevacizumab within protocol : ECOG5103 : A DoubleBlind Phase III Trial Doxorubicin Cyclophosphamide follow Paclitaxel Bevacizumab Placebo Patients Lymph Node Positive High Risk Lymph Node Negative Breast Cancer . ECOG1505 : A Phase III Randomized Trial Adjuvant Chemotherapy With Without Bevacizumab Patients With Completely Resected Stage IB ( &gt; 4 cm ) IIIA NonSmall Cell Lung Cancer ( NSCLC ) ECOG5202 : A Randomized Phase III Study Comparing 5FU , Leucovorin Oxaliplatin versus 5FU , Leucovorin , Oxaliplatin Bevacizumab Patients Stage II Colon Cancer High Risk Recurrence Determine Prospectively Prognostic Value Molecular Markers ECOG1305 : Phase III Randomized Trial Chemotherapy With Without Bevacizumab Patients Recurrent Metastatic Head Neck Cancer GOG0252 : A Phase III Clinical Trial Bevacizumab With IV Versus IP Chemotherapy Ovarian , Fallopian Tube Primary Peritoneal Carcinoma GOG0086P : A Three Arm Randomized Phase II Study Paclitaxel/Carboplatin/Bevacizumab , Paclitaxel/Carboplatin/Temsirolimus , Ixabepilone/Carboplatin/Bevacizumab Initial Therapy Measurable Stage III IVA , Stage IVB , Recurrent Endometrial Cancer ( Only arm include bevacizumab ) GOG0250 : A Randomized Phase III Evaluation Docetaxel Gemcitabine Plus GCSF Bevacizumab Versus Docetaxel Gemcitabine Plus GCSF Placebo Treatment Recurrent Advanced Leiomyosarcoma Uterus GOG0240 : A Randomized Phase III Evaluation Docetaxel Gemcitabine Plus GCSF Bevacizumab Versus Docetaxel Gemcitabine Plus GCSF Placebo Treatment Recurrent Advanced Leiomyosarcoma Uterus THO0640 : A Phase II Multi Center Study Investigating Translational Science ChemotherapyNaïve Patients Stage IIIB IV NonSmall Cell Lung Cancer ( NSCLC ) treat EGFRTKI , Erlotinib ( SPECS ) Eligibility Criteria : Patients ≥ 18 year age stage IV unresectable recurrent cancer ( except renal cell carcinoma glioblastoma multiforme ) get bevacizumab standard care . Patients ≥ 18 year age histologically confirm breast , colorectal nonsmall cell lung ( NSCL ) cancer complete surgical treatment stage I III cancer go initiate adjuvant therapy within one 3 clinical trial address role bevacizumab add chemotherapy adjuvant set breast , colorectal NSCL cancer ( E5103 , E1505 E5202 ) Patients ≥ 18 year age histologically confirm squamous cell carcinoma head neck ( recurrent metastatic ) initiate chemotherapy without bevacizumab within E1305 clinical trial . Patients ≥ 18 year age initiate chemotherapy bevacizumab within follow trial : GOG0252 , GOG0086P ( patient receive bevacizumab arm ) , GOG0250 , GOG0240 . Patients ≥ 18 year age histologic diagnosis non small cell lung cancer initiate bevacizumab within THO0640 clinical trial . Patients must provide informed write consent . Ineligibility Criteria Patients active renal cell carcinoma glioblastoma multiforme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>cardiovascular complication</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>